Baxalta rejects Shire's proposal, saying it undervalues the company

5 August 2015

USA-based Baxalta (NYSE: BXLT) has confirmed receipt Shire’s (LSE: SHP) unsolicited takeover approach, describing it as highly conditional.

Baxalta noted that it received this same proposal privately on July 10. In accordance with its fiduciary duties, Baxalta’s board of directors, in consultation with its financial and legal advisors, carefully reviewed the proposal and unanimously determined that it is not in the best interests of Baxalta or its shareholders.

Shire made its offer, an all-stock transaction valued at around $30 billion, public yesterday, adding to the flurry of acquisitions and mergers in the pharma sector, which so far this year has seen deals announced worth nearly $400 billion, an increase of 80% compared to a year ago, according to Thomson Reuters. Shire’s aim is to create a biotech power house in the rare diseases sector.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK